'STOP GAP' Clinical Trial

Pyoderma gangrenosum (PG) is a rare, ulcerating skin disease that is often secondary to inflammatory conditions such as Crohn’s disease and ulcerative colitis. A recent audit of patients with PG, including 11 centres in the UK, showed that 29% of patients also had inflammatory bowel disease.

A new trial is being funded by the National Institute for Health Research (NIHR), and is a UK Clinical Research Network portfolio study.

Given that PG is such a rare disease, we need your help to make this trial a success.

The trial website – provides a list of hospitals around the UK that are recruiting patients with PG into the trial. If you see a patient whom you suspect has PG, please consider referring to a dermatologist who is involved in the trial. Patients cannot be included in the trial if they have taken prednisolone or ciclosporin for 1 month prior to starting the trial, so it is important not to prescribe systemic therapy. Topical therapy can be prescribed if necessary.

For further details of the trial please follow the link below:

Further Information [ 3.3 Mb ]